Sant P. Chawla
桑特·查瓦拉
MD
Director, Sarcoma Oncology Research Center; Clinical Professor of Medicine, UCLA
👥Biography 个人简介
Sant P. Chawla, MD is Director of the Sarcoma Oncology Research Center in Santa Monica, California and Clinical Professor of Medicine at UCLA. He is one of the most prolific early-phase sarcoma trial investigators in the United States, with extensive experience in first-in-human and phase I/II studies of novel agents in soft tissue sarcomas. His center has been a leading site for trials of MDM2/CDK4-targeted agents, aldoxorubicin, palbociclib, and numerous other investigational drugs with relevance to specific sarcoma subtypes. Dr. Chawla's contributions include foundational work on MDM2 and CDK4 co-amplification in well-differentiated and dedifferentiated liposarcoma, supporting the development of CDK4 inhibitors and MDM2 antagonists as rational targets in these histotypes. He has authored over 200 peer-reviewed publications and served in leadership roles at CTOS and ASCO's Sarcoma Disease Committee.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CDK4 Amplification in Liposarcoma and Targeted Inhibition
Conducted pivotal early-phase studies of palbociclib and other CDK4/6 inhibitors in CDK4-amplified well-differentiated and dedifferentiated liposarcoma, demonstrating proof-of-concept for CDK4 inhibition in this genomically defined sarcoma and informing ongoing registrational trials.
MDM2 Antagonists in Liposarcoma
Led early-phase clinical trials of MDM2 inhibitors (including RG7112 and milademetan) in patients with MDM2-amplified dedifferentiated liposarcoma, establishing clinical activity and defining the tolerability profile of this drug class in the sarcoma setting.
Aldoxorubicin Development
Principal investigator for the pivotal phase II/III trials of aldoxorubicin (albumin-binding prodrug of doxorubicin) in advanced soft tissue sarcoma, demonstrating improved therapeutic index relative to conventional doxorubicin and contributing to understanding of tumor-pH-based drug delivery.
First-in-Human Sarcoma Trial Expertise
Developed the Sarcoma Oncology Research Center as a leading first-in-human and early-phase sarcoma trial site, enabling early access to novel compounds for patients with refractory disease and generating foundational clinical data across multiple drug classes.
Representative Works 代表性著作
Phase II Study of Palbociclib in Patients with Metastatic CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Journal of Clinical Oncology (2020)
Phase II study demonstrating clinical activity of palbociclib in CDK4-amplified liposarcoma with an acceptable safety profile, supporting the rationale for CDK4-directed therapy in this molecular subtype.
Phase 1 Trial of the MDM2 Inhibitor RG7112 in Patients with MDM2-Amplified Tumors
Clinical Cancer Research (2016)
First-in-human study of the MDM2 antagonist RG7112 demonstrating evidence of p53 pathway activation and clinical responses in MDM2-amplified tumors including dedifferentiated liposarcoma.
Randomized Phase 2/3 Trial of Aldoxorubicin versus Doxorubicin in Soft-Tissue Sarcoma
The Lancet Oncology (2015)
Randomized trial demonstrating improved progression-free survival with aldoxorubicin versus doxorubicin as first-line therapy for advanced soft tissue sarcoma, providing proof-of-concept for albumin-binding prodrug strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 桑特·查瓦拉 的研究动态
Follow Sant P. Chawla's research updates
留下邮箱，当我们发布与 Sant P. Chawla（Sarcoma Oncology Research Center, Santa Monica）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment